Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nestle Gains GI Diagnostics For Nutritional Health Biz Via Prometheus Deal

This article was originally published in The Gray Sheet

Executive Summary

Nestle Health Science will add gastrointestinal diagnostic services to its nutritional health business by acquiring Prometheus Laboratories for undisclosed terms in a deal announced May 24.

You may also be interested in...



Matchmaking And Integration In The New World Of Diagnostics M&A

Nontraditional buyers, including Big Pharmas, life science tool companies, diversified conglomerates, and even food companies, are snapping up molecular diagnostics assets with increasing frequency, applying a variety of models to enhance their businesses.

A Closer Look: Hutchison MediTech TCM Deal With Nestle Reaches Into Pharma Development

A new joint venture between Nestle Health Science and Chi-Med covering nutritional and medicinal products derived from botanical plants also includes Phase III drug HMPL-004, ending the Chinese R&D firm’s long search for a partner.

With Traditional Chinese Medicine Deal, Nestle’s Health Science Business Reaches Into Pharma Development

A new joint venture between Nestle Health Science and Chi-Med covering nutritional and medicinal products derived from botanical plants also includes Phase III drug HMPL-004, ending the Chinese R&D firm’s long search for a partner.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

MT030201

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel